Chulwoo Rhee

Chulwoo Rhee

Auto-generated profile, based on publicly available information

Chulwoo Rhee

International Vaccine Institute, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CRChulwoo Rhee
Chulwoo Rhee
GKGrishma A. Kharod
Grishma A. Kharod
NSNicolas Schaad
Nicolas Schaad
NFNathan W. Furukawa
Nathan W. Furukawa
NVNeil M. Vora
Neil M. Vora
KCKevin R. Clarke
Kevin R. Clarke
Acute febrile illness (AFI), a common reason for people seeking medical care globally, represents a spectrum of infectious disease etiologies with important variations geographically and by population. There is no standardized approach to conducting AFI etiologic investigations, limiting interpretation of data in a global context. We conducted a scoping review to characterize current AFI research methodologies, identify global research gaps, and provide methodological research standardization recommendations. Using pre-defined terms, we searched Medline, Embase, and Global Health, for publications from January 1, 2005–December 31, 2017. Publications cited in previously published systematic reviews and an online study repository of non-malarial febrile illness etiologies were also included. We screened abstracts for publications reporting on human infectious disease, aimed at determining AFI etiology using laboratory diagnostics. One-hundred ninety publications underwent full-text review, using a standardized tool to collect data on study characteristics, methodology, and laboratory diagnostics. AFI case definitions between publications varied: use of self-reported fever as part of case definitions (28%, 53/190), fever cut-off value (38·0°C most commonly used: 45%, 85/190), and fever measurement site (axillary most commonly used: 19%, 36/190). Eighty-nine publications (47%) did not include exclusion criteria, and inclusion criteria in 13% (24/190) of publications did not include age group. No publications included study settings in Southern Africa, Micronesia & Polynesia, or Central Asia. We summarized standardized reporting practices, specific to AFI etiologic investigations that would increase inter-study comparability. Wider implementation of standardized AFI reporting methods, with multi-pathogen disease detection, could improve comparability of study findings, knowledge of the range of AFI etiologies, and their contributions to the global AFI burden. These steps can guide resource allocation, strengthen outbreak detection and response, target prevention efforts, and improve clinical care, especially in resource-limited settings where disease control often relies on empiric treatment. PROSPERO: CRD42016035666. Acute febrile illness (AFI) is a common reason for people seeking medical care globally with potentially serious infectious etiologies. However, AFI has no current consensus standardized approach when considered as a syndromic case definition for public health surveillance or research, especially in global settings where AFI treatment is performed with limited diagnostic availability. Therefore, the aim of this review was to describe current methodologies in AFI research, identify gaps in research, and provide recommendations for standardization of AFI research. We screened abstracts and completed full-text reviews on publications found through an extensive search. A total of 190 publications were included in the final review, from which we collected data on study characteristics, methodology, and laboratory diagnostics. These collected data elements allowed us to identify where there were inconsistencies in reporting and investigative methods, which data elements were not regularly collected, and what laboratory testing methods were commonly used. Standardized reporting methods for AFI investigations, along with laboratory testing capacity for multiple pathogens, can improve our knowledge of the causative agents of AFI in certain regions of the world. This can help us determine where resources are needed, how to strengthen outbreak detection and response, and how to improve medical care, especially in regions with limited resources.

4 March 2023 in IJID Regions
Verified
Journal Article
Open access
SVSompong Vongpunsawad
Sompong Vongpunsawad
CRChulwoo Rhee
Chulwoo Rhee
PNPornjarim Nilyanimit
Pornjarim Nilyanimit
NPNimesh Poudyal
Nimesh Poudyal
SJSuchada Jiamsiri
Suchada Jiamsiri
YPYong Poovorawan
Yong Poovorawan
Objective: The aim of this study was to determine the prevalence of high-risk (HR) and vaccine-type human papillomavirus (HPV) infection among Thai schoolgirls who were not included in the national HPV immunization program.Methods: Cross-sectional surveys were conducted among grade 10 (15-16 years old) and grade 12 (17-18 years old) schoolgirls in two provinces of Thailand. Urine samples were collected using the Colli-PeeRO device from November 2018 to February 2019. The samples were initially tested using CobasRO 4800. Subsequently, all Cobas-positive samples and 1:1 matched Cobas-negative samples were tested by Anyplex RO assay. Prevalences of any HPV, any HR HPV, vaccine-type HPV, and individual HR HPV types were estimated by school grade.Results: Prevalences of any HPV and any HR HPV were 11.6% and 8.6% for grade 10, and 18.5% and 12.4% for grade 12 schoolgirls, respectively. Prevalences of bivalent vaccine-type HPV infection in grades 10 and 12 were 3.4% and 4.5%, respectively. Prevalences of quadrivalent and nonavalent vaccine-type HPV infections were 4.0%/6.6% and 6.4%/10.4% in grades 10 and 12, respectively. HPV16 was the most common type detected, followed by HPV58, 51, and 52. Circulating HR HPV types were similar between the school grades.Conclusion: A substantial burden of HR HPV infections was found among unvaccinated high school girls in Thailand.

23 December 2024 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CRChulwoo Rhee
Chulwoo Rhee
ADAmy Dighe
Amy Dighe
NKNishan Katuwal
Nishan Katuwal
HCHaeun Cho
Haeun Cho
RMRamzi Mraidi
Ramzi Mraidi
JLJulia Lynch
Julia Lynch
Background: Hepatitis E virus (HEV) causes acute jaundice and poses an important public health problem in low- and middle-income countries. Limited surveillance capacity and suboptimal access to diagnostics leads to under-reporting of HEV infections in affected countries, including Nepal. Serum antibodies against HEV are indicative of past infection. We analyzed existing samples from a nationally representative serosurvey to describe the geospatial distribution and factors associated with HEV seroprevalence in Nepal, as a proxy for infection. Methodology/Principle findings: A nationally representative cross-sectional serosurvey of 3,922 individuals ≥2 years old from 975 households spread across 65 wards throughout Nepal was conducted between November 2021 and January 2022. Bio-banked samples were tested for anti-HEV IgG. Seroprevalence and its 95% confidence interval were estimated by age, sex, ecological region, municipality type, and other waterborne-disease related risk factors. Bayesian geostatistical models were fitted to observed seroprevalence data and used to generate high-resolution maps of seroprevalence across Nepal. Available samples from 3,707 participants were tested for anti-HEV IgG, and 3,703 were used for final analysis. We found 20.8% (95% CI: 19.5–22.2) of participants had evidence of prior HEV infection. HEV seroprevalence increased with age, and was higher in males (23.5%, 95% CI: 21.5–25.5) than in females (18.6%, 95% CI: 16.9–20.3). Seroprevalence in hilly (28.9%, 95% CI: 26.6–31.2) and mountain (24.6%, 95% CI: 18.8–30.5) regions were significantly higher than in terai (14.2%, 95% CI: 12.7–15.8). While there was no significant difference between urban and rural populations, the predicted seroprevalence was highest in Kathmandu, the capital of Nepal, reaching seroprevalence of 50% in some selected area. No statistically significant differences were found for wealth quintile, water source, and toilet facility. Conclusions: This study provides population-based serologic evidence that HEV is endemic in Nepal, with the greatest risk of infection in Kathmandu.

7 August 2021 in International Journal of One Health
Verified
Journal Article
Open access
SKSeulgi Kim
Seulgi Kim
CRChulwoo Rhee
Chulwoo Rhee
SKSu Jin Kang
Su Jin Kang
STSangwoo Tak
Sangwoo Tak
Background and Aim: Little is known about data integration in public health research and its impact. This study aimed to summarize known collaboration information, the characteristics of the datasets used, the methods of data integration, and knowledge gaps. Materials and Methods: We reviewed papers on infectious diseases from two or more datasets published during 2009- 2018, before the coronavirus disease pandemic. Two independent researchers searched the Medline and Global Health databases using predetermined criteria. Results: Of the 2375 items retrieved, 2272 titles and abstracts were reviewed. Of these, 164 were secondary reviews. Full-text reviews identified 153 relevant articles; we excluded 11 papers that did not meet our inclusion criteria. Of the 153 papers, 150 were single-country studies. Most papers were from North America (n=47). Viral diseases were the most commonly researched diseases (n=66), and many studies sought to define infection rates (n=62). Data integration usually employed unique national identifiers (n=37) or address-based identifiers (n=30). Two data sources were combined (n=121), and at least one data source typically included routine surveillance information. Conclusion: We found a growing usage of data integration in infectious diseases, emphasizing the advantages of data integration and linkage analysis, and reiterating its importance in public health emergency preparedness and response.

1 October 2024 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
SJSuchada Jiamsiri
Suchada Jiamsiri
CRChulwoo Rhee
Chulwoo Rhee
HAHyeon Seon Ahn
Hyeon Seon Ahn
HSHyeong-Won Seo
Hyeong-Won Seo
WKWorrawan Klinsupa
Worrawan Klinsupa
JLJulia Lynch
Julia Lynch
Background: With accumulating evidence of single-dose human papillomavirus (HPV) vaccine efficacy in young women, we conducted a community vaccine effectiveness study comparing HPV single-dose and 2-dose regimens (0 and 6 months) of a bivalent HPV vaccine among grade 8 schoolgirls (aged 13-14 years) in Thailand. Methods: In 2018, eligible grade 8 schoolgirls in Udon Thani (single dose) and Buri Ram (2 doses) provinces were offered HPV vaccine per assigned dose regimen. Concurrently, a cross-sectional survey for measuring baseline HPV prevalence was conducted in grade 10 (n = 2600) and grade 12 unvaccinated schoolgirls (n = 2000) in each province. HPV infection was assessed in first-void urine samples, tested by DNA polymerase chain reaction on the cobas 4800 system (Roche Molecular Diagnostics, Pleasanton, CA). All samples positive on the cobas system and an equal number of negative samples were also tested by Anyplex II HPV28 Detection (Seegene, Seoul, South Korea). The surveys were repeated in 2020 and 2022, when vaccinated grade 8 schoolgirls reached grade 10, and then subsequently grade 12, respectively. Vaccine effectiveness was estimated by comparing the weighted prevalence of HPV-16 or HPV-18 between grade-matched unvaccinated schoolgirls on the baseline survey (2018) and vaccinated schoolgirls in the year-2 (2020) and year-4 (2022) surveys. Adjustment methods were used in the analysis to account for potential differences in sexual behavior due to the noncontemporaneous comparison. Results: The prevalence of HPV-16 and HPV-18 on the baseline survey among unvaccinated grade 10/grade 12 schoolgirls was 2.90% (95% confidence interval [CI] = 2.54% to 3.31%)/3.98% (95% CI = 3.52% to 4.49%) for Udon Thani and 3.87% (95% CI = 3.46% to 4.34%)/6.13% (95% CI = 5.56% to 6.75%) for Buri Ram. On the year-2 survey, the prevalence among vaccinated grade 10 schoolgirls was 0.57% (95% CI = 0.42% to 0.77%) for Udon Thani and 0.31% (95% CI = 0.21% to 0.47%) for Buri Ram. The 2-year postvaccination crude vaccine effectiveness for the single-dose regimen was estimated at 80.4% (95% CI = 73.9% to 86.9%), and for the 2-dose regimen at 91.9% (95% CI = 88.5% to 95.4%). On the year-4 survey, the prevalence among vaccinated grade 12 schoolgirls was 0.37% (95% CI = 0.25% to 0.56%) for Udon Thani and 0.28% (95% CI = 0.18% to 0.45%) for Buri Ram. Four-year postvaccination crude vaccine effectiveness for the single-dose regimen was estimated at 90.6% (95% CI = 86.6% to 94.6%) and for the 2-dose regimen was estimated at 95.4% (95% CI = 93.2% to 97.6%). All adjustment methods minimally affected vaccine effectiveness for the single-dose and 2-dose regimens. At 4 years after vaccination, the difference in crude vaccine effectiveness between the single-dose and 2-dose regimens was ‒4.79% (95% CI = ‒9.32% to ‒0.25%), meeting the study’s noninferiority criteria. Conclusions: Our study demonstrated that both single-dose and 2-dose HPV vaccination significantly decreased HPV-16/18 point prevalence 2 years and 4 years after vaccination. Crude vaccine effectiveness at 4 years after vaccination was greater than 90% for both the single-dose and 2-dose regimens; the single-dose regimen was not inferior to the 2-dose regimen. These data show that a single dose of HPV vaccine provides high levels of protection when administered to schoolgirls younger than 15 years of age.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
SJSuchada Jiamsiri
Suchada Jiamsiri
CRChulwoo Rhee
Chulwoo Rhee
HAHyeon Seon Ahn
Hyeon Seon Ahn
HSHyeong Won Seo
Hyeong Won Seo
WKWorrawan Klinsupa
Worrawan Klinsupa
JLJulia Lynch
Julia Lynch
Background: With accumulating evidence single dose (SD) HPV vaccine efficacy in young women, we are conducting a community vaccine effectiveness (VE) study comparing HPV SD and 2-dose (2D) regimens (0, 6 months) of a bivalent HPV vaccine, in Thailand among 13-14 year-old Grade 8 schoolgirls. Methods: In 2018, eligible Grade 8 schoolgirls in Udon Thani (SD) and Buriram (2D) provinces were offered HPV vaccine per assigned dose regimen. Concurrently, a cross-sectional survey (CSS) of HPV prevalence was conducted in Grade 10 schoolgirls (N=2,600 in each province). HPV infection was assessed in first-void urine samples, tested by DNA PCR Cobas 4800. All Cobas positive samples and an equal number of negative samples were also tested by Anyplex II HPV 28. In 2020, when vaccinated Grade 8 schoolgirls reached Grade 10, the CSS was repeated. VE was estimated by comparing weighted prevalence of HPV 16 or 18 between baseline CSS (2018) and vaccinated schoolgirls in Year-2 CSS (2020). Adjustment methods were used in the analysis to account for potential differences in sexual behavior due to the non-contemporaneous comparison. Findings: Prevalence of HPV16 or 18 in baseline CSS was 2.92% (95% CI 2.57-3.33) and 3.40% (95% CI 3.04-3.81) for Udon Thani and Buriram, respectively. In Year-2 CSS, the prevalence among vaccinated schoolgirls was 0.50% (95% CI 0.34-0.71) for Udon Thani and 0.22% (95% CI 0.14-0.35) for Buriram. Estimated unadjusted VE for SD was 83.0% (95% CI: 76.4-89.6), and for 2D was 93.6% (95% CI: 90.5-96.8). All adjustment methods minimally impacted VE estimates for SD (80%~83%) and 2D (91%~93%). Interpretation: Two years post-vaccination with SD HPV vaccination, estimated VE against HPV 16 and 18 infection was high among teenage schoolgirls in Thailand. Trial Registration Details: The study is registered at clinicaltrials.gov with the identifier NCT03747770. Funding Information: This study was funded by the Bill & Melinda Gates Foundation. Declaration of Interests: All authors declare having no conflict of interest. Ethics Approval Statement: The study protocol was approved by the Thailand Ministry of Public Health (MoPH) Ethical Committee (EC), the International Vaccine Institute Institutional Review Board, and the Chulalongkorn University EC.